Navigation Links
Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
Date:8/15/2013

and Brigham and Women's Hospital to research that analyzes real-world data to help enhance patient health and ensure patients with NVAF have additional information about treatments available to help reduce the risk of debilitating and potentially fatal strokes. In addition to this study program, Boehringer Ingelheim launched the GLORIATM-AF registry program in April 2012, a worldwide registry with the aim of understanding the long-term use of OAC therapy in the reduction of NVAF-related stroke risk in a real-world setting.

"Our support of the study program being conducted by Brigham and Women's Hospital is a sign of our shared commitment to help improve healthcare delivery and outcomes for the estimated five million patients with non-valvular atrial fibrillation in the U.S. who are at increased risk for stroke," said Sabine Luik, M.D., senior vice president, medicine & regulatory affairs, U.S. regional medical director, Boehringer Ingelheim Pharmaceuticals, Inc. "As a science-based company, Boehringer Ingelheim considers patient safety and education as top priorities and we remain dedicated to research and education which fosters greater public health."

About Pradaxa® (dabigatran etexilate mesylate) Capsules

Indications and Usage 
Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

WARNING: DISCONTINUING PRADAXA IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE. Discontinuing PRADAXA places patients at an increased risk of thrombotic events. If anticoagulation with PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.

CONTRAINDICATIONS 
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
2. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
3. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
4. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
5. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
11. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 CEFALY Technology , ... stimulation device specifically authorized for use prior to the ... a new PET trial showing that the Cefaly device ... brain in migraine patients, namely the orbitofrontal cortex and ... scan, which is an imaging test of the brain, used a radioactive ...
(Date:6/1/2015)... SETAUKET, N.Y. , June 1, 2015 /PRNewswire/ ... (NASDAQ: HRTX ) today announced positive, top-line ... study.  MAGIC evaluated the efficacy and safety of ... candidate SUSTOL ® (granisetron injection, extended release) ... intravenous (IV) neurokinin-1 (NK 1 ) receptor antagonist ...
(Date:6/1/2015)... 2015   OTC Markets Group Inc. ... financial marketplaces for 10,000 U.S. and global securities, ... Diego -based biopharmaceutical company, on its NASDAQ ... public venture market for entrepreneurial and development stage ... "We,re happy to congratulate OncoSec ...
Breaking Medicine Technology:New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2New cancer therapy study results - MAGIC Trial 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
(Date:6/2/2015)... June 02, 2015 Colleen’s Dream Foundation ... granted $70,000 to the UNMC to support ovarian cancer research ... Cundiff, a member of the Colleen’s Dream Foundation Board of ... the biggest to date for Colleen’s Dream Foundation and they ... Omaha. , “Dr. Wang is a rising star in the ...
(Date:6/2/2015)... June 02, 2015 While the movie ... of comic books, comic books themselves are stepping into ... Uniting Nations plans to produce educational comics in multiple ... Goals for Sustainable Development - an international effort to ... hunger, health, education, sustainable energy, inequality, climate change and ...
(Date:6/2/2015)... 02, 2015 Pacifica Graduate Institute ... up by current and former students to honor the ... member from 2002 until his death in 2013. His ... depth of feeling, as well as his passion for ... as an analyst, teacher, and writer were felt in ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Lynn Lester as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... Lester with this prestigious award,” said NAPW President Star ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Linda Cade as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” said NAPW President Star Jones. ...
Breaking Medicine News(10 mins):Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2
... RIDGE, N.J., Oct. 19 VioQuest,Pharmaceuticals (OTC ... focused on acquiring, developing and,commercializing targeted cancer ... data in poster presentations pertaining to VQD-002 ... and Cancer Therapeutics",International Conference sponsored by the ...
... CSV ) today announced plans to release 2007 third quarter ... conjunction with the,release, Carriage Services has scheduled a conference call, ... 2, 2007 at 10:00,a.m. eastern time. What: ... When: Friday, November 2, 2007 ...
... Amedisys, Inc.,(Nasdaq: AMED or the "Company"), one of ... intends to release its financial,results for the quarter ended ... Company will also host a conference call with the,investment ... To participate in the conference call, please dial 800-683-1525,(Domestic) ...
... US Oncology Holdings, Inc. and its,operating subsidiary, US ... on Thursday, November 8, 2007. A conference ... at 10:00,a.m., EST, for the company,s bondholders following ... representatives of US Oncology,s management,team will discuss the ...
... poor, uninsured,women in Pennsylvania will no longer have ... Prevention Project has ended. "Poor,women are going to ... funding for this critical program," declared Dorothy Mann, ... "We had a,Democratic supporter who worked with a ...
... Association of,Dental Plans (NADP) calls on Congress and the ... Program (CHIP).,Specifically, NADP urges prompt action to enact the ... bill., In letters to congressional health policy leaders, ... Dental services should be a mandatory CHIP benefit. ...
Cached Medicine News:Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 2Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 3Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 4Health News:VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting 5Health News:Carriage Services Announces Third Quarter Earnings Release and Conference Call Schedule 2Health News:Amedisys to Host Conference Call to Discuss Third Quarter Financial Performance and Operating Results 2Health News:Pa. Funding for Cervical Cancer Prevention Services Ends 2Health News:NADP Calls on Congress and the White House to Work Together to Cover Children's Dental Health 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: